Brexit: UK To Change Drug Import And Export Rules From 2021
Guidance Explains When Written Confirmations Will Be Needed For APIs
Executive Summary
New guidance documents issued by the UK regarding medicines regulation after the end of the Brexit transition period cover the import of medicinal products from countries on an approved list, trade in APIs between the UK and third countries, and the acceptance of batch testing under existing mutual recognition agreements.
You may also be interested in...
Brexit: UK Industry Body Slams 'Ill Considered' Guidance On Batch Testing
The UK BioIndustry Association says the updated guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
UK Explains Post-Brexit Pediatric Study Processes
The Medicines and Healthcare products Regulatory Agency has outlined the various common scenarios that may occur when companies submit a UK pediatric investigation plan after the Brexit transition period has expired.
European Parliament Wants EU-Wide Pull Incentive Scheme For New Antimicrobials
The three major EU institutions are all calling for urgent action to tackle antimicrobial resistance, with the emphasis very much on incentives for the development of novel medicines and a reduction in overall consumption of antibiotics.